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Abstract
Lymphatic malformations (LM) are characterized by the overgrowth of lymphatic vessels
during pre- and postnatal development. Macrocystic, microcystic and combined forms of
LM are known. The cysts are lined by lymphatic endothelial cells (LECs). Resection and
sclerotherapy are the most common treatment methods. Recent studies performed on LM
specimens in the United States of America have identified activating mutations in the phos-
phatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene in LM.
However, whole tissue but not isolated cell types were studied. Here, we studied LM tissues
resected at the University Hospitals Freiburg and Regensburg, Germany. We isolated LECs
and fibroblasts separately, and sequenced the commonly affected exons 8, 10, and 21 of
the PIK3CA gene. We confirm typical monoallelic mutations in 4 out of 6 LM-derived LEC
lines, and describe two new mutations i.) in exon 10 (c.1636C>A; p.Gln546Lys), and ii.) a
3bp in-frame deletion of GAA (Glu109del). LM-derived fibroblasts did not possess such
mutations, showing cell-type specificity of the gene defect. High activity of the PIK3CA—
AKT- mTOR pathway was demonstrated by hyperphosphorylation of AKT-Ser473 in all LM-
derived LECs (including the ones with newly identified mutations), as compared to normal
LECs. Additionally, hyperphosphorylation of ERK was seen in all LM-derived LECs, except
for the one with Glu109del. In vitro, the small molecule kinase inhibitors Buparlisib/BKM-
120, Wortmannin, and Ly294002, (all inhibitors of PIK3CA), CAL-101 (inhibitor of PIK3CD),
MK-2206 (AKT inhibitor), Sorafenib (multiple kinases inhibitor), and rapamycin (mTOR
inhibitor) significantly blocked proliferation of LM-derived LECs in a concentration-depen-
dent manner, but also blocked proliferation of normal LECs. However, MK-2206 appeared
to be more specific for mutated LECs, except in case of Glu109 deletion. In sum, children
that are, or will be, treated with kinase inhibitors must be monitored closely.
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Introduction
Lymphatic malformations (LM), also known as lymphangiomas, are characterized by the over-
growth of lymphatic vessels during pre- and postnatal development. They are most frequently
found in the head and neck region but may be located in any organ containing lymphatics.
Macro-cystic, micro-cystic and combined forms of LM are distinguished in the clinical diag-
nosis, the cysts being lined by lymphatic endothelial cells (LECs), which express typical LEC
markers such as LYVE-1, Podoplanin (PDPN), PROX1, VEGFR-3 and CD31/PECAM-1 [1–
5], although, however, the expression of PDPN/D2-40 has not been found in 4 of 12 LM [6].
The etiology of LM has long been under debate. Recent studies have identified activating
mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
(PIK3CA) gene in lymphovascular overgrowth disorders, with five specific mutations account-
ing for the majority of cases [7]. Such mutations, in combination with other oncogenic muta-
tions, are also known to enhance tumor growth [8]. In a cohort of 31 LM patients from the
Seattle Children’s Hospital, 74% showed activating PIK3CA mutations; and even more signifi-
cantly, 16 out of 17 LM patients from the Boston Children’s Hospital had PIK3CA mutations
[7]. The tissues investigated in these studies contained many different cell types, and, although
activating PIK3CA mutations have also been found in five LM-derived LEC lines isolated in
the United States of America [9, 10], a direct comparison of different LM patient-derived cell
lines has not been performed. We had access to tissue from 6 LM patients from the University
Hospitals Freiburg and Regensburg, Germany. We isolated LM-derived LECs (Ly-LEC) and
fibroblasts (Ly-F) and screened each cell type for the commonly affected exons 8, 10, and 21 of
the PIK3CA gene. We identified 4 typical and two new activating mutations in the Ly-LEC
lines, but never in fibroblasts, showing LEC-specificity of the mutation in LM. In search for
specific inhibitors we treated Ly-LECs with 7 different kinase inhibitors, in comparison to nor-
mal foreskin-derived LECs. We observed significant reduction in proliferation of Ly-LECs
with all of the inhibitors, but it must be pointed out that normal LECs behaved in the same or
similar manner. Therefore, caution is advisable when treating young LM patients with kinase
inhibitors, but a therapeutic window for such treatment may exist.
Results
Recent studies have identified activating mutations in the PIK3CA gene in lymphovascular
overgrowth disorders, with five specific mutations (in exons 8, 10, and 21) accounting for the
majority of cases [7]. We isolated lymphangioma/lymphatic malformation (LM)-derived lym-
phatic endothelial cells (Ly-LEC) and fibroblasts (Ly-F) from 6 patients (Table 1). Growth
characteristics and the expression of CD31 and PROX1 of Ly-LECs were compared to healthy
human dermis/foreskin-derived HD-LECs. While HD-LECs showed a cobblestone morphol-
ogy, CD31 expression in the cell membrane, and a robust nuclear PROX1 expression (Fig 1A
and 1B), Ly-LECs showed a more variable PROX1 expression, heterogeneity in cell size, and
sometimes a double nucleus (Fig 1C–1E). Patient-derived fibroblasts were characterized by the
absence of CD31 and PROX1 (Fig 1F), typical morphology and growth characteristics, as well
as their α-smooth muscle actin (αSMA) and vimentin expression (Fig 2).
We isolated genomic DNA and tested Ly-LECs and corresponding fibroblasts for activating
PIK3CA mutations in exons 8, 10, and 21. In the first cell line (Ly-LEC-1), previously published
as LEC-A or LEC-1 [11], we found the mutation c.1258T>C (p.C420R) in exon 8 (Table 1),
which increases the enzyme’s baseline catalytic activity. We did not find mutations in fibro-
blasts (Ly-F-1) of the patient. In the second cell line, Ly-LEC-2, previously published as
LEC-B/LEC-2 [11], we did not find a typical PIK3CA mutation in exons 8, 10, and 21, which
also holds true for the fibroblasts from the same patient (Table 1). We therefore sequenced the
PIK3CA mutations in lymphatic malformations
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Abbreviations: AKT, AKT subfamily of serine/
threonine kinases; CD31/PECAM-1, Platelet
endothelial adhesion molecule-1; CLOVES,
Congenital lipomatous overgrowth with vascular,
epidermal and skeletal anomalies; EGM-2,
Endothelial growth medium-2; ERK, Extracellular
signal-regulated kinases; FAVA, Fibro-adipose
vascular anomaly; HD-LEC, Human dermal
lymphatic endothelial cell; KTS, Klippel-Trenaunay
syndrome; LEC, Lymphatic endothelial cell; Ly-F,
Lymphatic malformation (lymphangioma)-derived
fibroblast; Ly-LEC, Lymphatic malformation
(lymphangioma)-derived lymphatic endothelial cell;
LYVE-1, Lymphatic vessel endothelial hyaluronic
acid receptor-1; mTOR, Mechanistic target of
rapamycin; PDPN, Podoplanin; PIK3CA,
Phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha; PROX-1, Prospero-related
homeobox transcription factor-1; VEGF-C, Vascular
endothelial growth factor-C; VEGFR-3, Vascular
endothelial growth factor receptor-3.
Table 1. Mutation analysis of LM-derived cell-lines.
Cell line (alternative name) Mutation (PIK3CA) Gender Age
Ly-LEC-1 (LEC-A; LEC-1) Exon 8: c.1258T>C (p.C420R) male Infant
Ly-F-1 No mutation in exons 8, 10, 21
Ly-LEC-2 (LEC-B; LEC-2) 3 bp in-frame GAA deletion; Glu109del (new) male Infant
Ly-F-2 No mutation in exons 8, 10, 21
Ly-LEC-10 Exon 10: c.1636C>A (p.Q546K) (new) female Infant
Ly-F-10 No mutation in exons 8, 10, 21
Ly-LEC-12 Exon 10: c.1633G>A (p.E545K) female Infant
Ly-F-12 No mutation in exons 8, 10, 21
Ly-LEC-14 Exon 21: c.3140A>T, (p.H1047L) female Adult
Ly-F-14 No mutation in exons 8, 10, 21
Ly-LEC-17 Exon 10: c.1633G>A (p.E545K) male Adult
Ly-F-17 No mutation in exons 8, 10, 21
HD-LECc2 No mutation in exons 8, 10, 21 male Infant
HD-LECc3 No mutation in exons 8, 10, 21 male Infant
HD-LECc4 No mutation in exons 8, 10, 21 male Infant
HD-LEC represent LECs from healthy donors. All other cells were isolated from LM patients. LY-LEC are LM-
derived LECs, Ly-F are LM-derived fibroblasts.
https://doi.org/10.1371/journal.pone.0200343.t001
Fig 1. Culture of lymphatic endothelial cells and fibroblasts. Immunocytology showing CD31 (green) and PROX1 (magenta). Nuclei are counter-stained with
DAPI (blue). A) Foreskin-derived HD-LECc4; B) Foreskin-derived HD-LECc2; C) Patient-derived Ly-LEC-12, D) Patient-derived Ly-LEC-2; E) Patient-derived
Ly-LEC-10; F) Patient-derived fibroblasts (Ly-F-12) do not express CD31 or PROX1. Bar = 45 μm in A-D,F, and 90 μm in E.
https://doi.org/10.1371/journal.pone.0200343.g001
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whole PIK3CA gene in Ly-LEC-2 and found a 3bp in-frame GAA deletion in position 109 or
110 (there are two consecutive glutamic acids), previously described as Glu109del in carcino-
mas such as breast, endometrium, pancreas, and esophagus [12, 13]. Its effect on PIK3CA pro-
tein function, however, has remained unknown.
In Ly-LEC-10 we found a mutation in exon 10 (c.1636C>A; p.Gln546Lys), which has not
been detected before in LECs, however, has been found in tumor cells [14, 15]. Again, its effect
on PIK3CA protein function has remained unknown. In Ly-F-10 the mutation was not pres-
ent. In Ly-LEC-12 and Ly-LEC-17 the mutation c.1633G>A (p.E545K) in exon 10 was found,
which was not present in the fibroblasts from the same patients. In Ly-LEC-14 the mutation
c.3140A>T, p.(H1047L) in exon 21 was found, and was not present in corresponding
fibroblasts.
In sum, in 4 Ly-LEC lines we found an activating PIK3CA mutation. In two case (Ly-LEC2
and 10) we found a new mutation, with as yet unknown effects. Corresponding fibroblasts
were always negative (Table 1).
Signal transduction of PIK3CA via the kinases AKT and mTOR has been well documented
in tumor growth and angiogenesis [16]. We studied phosphorylation of AKT at position
Fig 2. Patient-derived fibroblasts (Ly-F-12). A) Phase-contrast image showing typical morphology. B) Anti-αSMA staining. C) Anti-vimentin staining. D)
Negative control without primary antibodies. Note that all fibroblasts express αSMA and vimentin. Bar = 50μm.
https://doi.org/10.1371/journal.pone.0200343.g002
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serine473 of Ly-LECs in comparison to normal HD-LECs and observed hyper-phosphoryla-
tion of AKT-Ser473 in all Ly-LECs, clearly showing their highly activated, angiogenic state
(Fig 3). Thereby, AKT hyperphosphorylation was also seen in Ly-LEC2 and Ly-LEC10, which
shows that the newly identified mutations also function as activating mutations. Phosphoryla-
tion of the mitogen-activated kinase ERK has also been shown to be a marker for angiogenic
endothelial cells. We found hyperphosphorylation in all LM-derived LECs studied, except for
Ly-LEC-2 (Fig 4), indicating a specific effect of Glu109del in LECs.
In search for a kinase inhibitor with high specificity for PIK3CA-mutated LECs, we com-
pared the anti-proliferative effects of 7 different kinase inhibitors on Ly-LECs (n = 3) and nor-
mal HD-LECs (n = 3). We studied Buparlisib (BKM120), Wortmannin, and Ly294002 (to
inhibit PIK3CA), CAL-101/Idelalisib (to inhibit PIK3CD), MK-2206 (to inhibit AKT), Sorafe-
nib (a multi-kinase inhibitor), and rapamycin (to inhibit mTOR). We observed significant
dose-dependent growth inhibition with all inhibitors used, however, almost the same or simi-
lar responses were noted for normal HD-LEC (Figs 5–11). We did not immediately find an
exclusive inhibitor for all LM-derived LECs, although it may be worth to test MK-2206 in
greater detail. In 2 mutated cell lines (Ly-LEC1, Ly-LEC12) MK-2206 (25 μM) reduced cell
numbers after 48h below the initial value. This was not the case in the 3 normal LEC lines (Fig
9). The only exception, Ly-LEC-2, seems to have an ’atypical’ PIK3CA mutation, and shows no
ERK hyperphosphorylation.
Fig 3. A,B. Phospho-AKT-Ser473 Western blot analysis of lymphatic endothelial cells. Note that phospho-
AKT-Ser473 (pAKT) is highly expressed in lymphatic malformation-derived LECs (Ly-LEC1, 2, 10, and 12), but not in
normal HD-LECc3 and c4. Total AKT (tAKT) is found in all cell lines. Antibodies against α-tubulin were used as
loading control.
https://doi.org/10.1371/journal.pone.0200343.g003
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Discussion
Origin of lymphatic endothelial cells (LECs)
Vascular malformations (VM) can affect any type of vessel; blood vessels as well as lymphatics,
isolated or in combined forms. A number of mutations, mostly loss of function mutations,
have been identified to cause VM [17]. The combination of venous and lymphatic malforma-
tions is obviously rooted in the common origin of the two types of endothelial cells. Precursors
for LECs reside in the lining of specific embryonic veins, but also in various mesenchymal
compartments of vertebrate embryos [18, 4, 19]. Lymphangioblasts are still present in adult
mouse lung [20], and also in the human, where they contribute to inflammation-induced lym-
phangiogenesis [21]. Smooth muscle cells in the tunica media of vessels originate from many
different embryonic compartments [22]. In lymphatic collectors, they are in intimate contact
with the luminal LECs, and, at transmission electron microscopic level, present as heteroge-
nous population of cells [23]. Among the indispensable regulators of lymphangiogenesis are
Vascular Endothelial Growth Factor-C (VEGF-C) and its high affinity receptor VEGFR-3 [24,
25, 4]. Loss of function mutations of VEGFR-3 are the main cause of congenital (primary)
lymphedema, due to hypoplasia of the lymphatics [26].
Activating PIK3CA mutations in LECs of lymphatic malformations
The reasons for hyperplasia of lymphatics have long been unknown, however, recently it has
been shown that lymphatic malformations (LM), isolated and in combination with other over-
growth syndromes, are mostly caused by activating mutations in the PIK3CA gene. Mutations
have been found in 74% of 31 individuals with isolated LM in a cohort from the Seattle Chil-
dren’s Hospital [7], and in a cohort from the Boston Children’s Hospital even>90% (16 of 17)
LM were somatic mosaic for specific PIK3CA mutations. However, no significant correlation
between type of mutation, macro-cystic or micro-cystic LM, or clinical severity could be
observed [7]. Similarly, when LM is part of a complex syndrome, PIK3CA is of major
Fig 4. Phospho-ERK Western blot analysis of lymphatic endothelial cells. Note that phospho-ERK (pERK) is highly
expressed in lymphatic malformation-derived Ly-LECs (Ly-LEC1, 10, and 12), but not in normal HD-LECc3 and c4.
Ly-LEC2, which contain a Glu109del in PIK3CA, are similar to normal LECs, which contain clear levels of total ERK
(tERK). Antibodies against α-tubulin were used as loading control.
https://doi.org/10.1371/journal.pone.0200343.g004
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importance. It has been shown that 19 of 21 individuals with Klippel-Trenaunay syndrome
(KTS), 5 of 8 with fibro-adipose vascular anomaly (FAVA), and 31 of 33 with congenital lipo-
matous overgrowth with vascular, epidermal and skeletal anomalies (CLOVES) were mosaic
for specific PIK3CA mutations [7]. Thereby, 5 recurrent mutations have been found in the
majority (~80%) of cases, resulting in amino acid exchange p.C420R, p.E542K, p.E545K,
p.H1047R, and p.H1047L [7]. However, the authors also noted that the number of mutated
cells in the LM tissue was less than 10%.
Therefore, we isolated both LECs and fibroblasts from LM tissues of 6 patients, and
screened the commonly affected exons 8, 10, and 21 of the PIK3CA gene. Of note, a change
in exon numbering of PIK3CA has taken place. Since exon 1 is entirely UTR, numerous previ-
ous studies have numbered the exons according to the coding exons. As a result, these studies
refer to E545 mutations as being in exon 9 and H1047 mutations in exon 20 [27]. However,
Fig 5. Proliferation studies with PIK3CA inhibitor Buparlisib (BKM120) on Ly-LEC (left side, A—C) and
HD-LEC (right side, D—F), after 0, 24, 48 and 72 hours (h). 0 h values were set to 100%. Concentrations are
indicated. Shown are the mean values of n = 3 independent experiments with each 5–8 replicates.
https://doi.org/10.1371/journal.pone.0200343.g005
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according to the recommendations of the Human Genome Variation Society (HGVS) exon
numbering should always start with exon 1 as it appears, including also non-coding exons
(www.hgvs.org/mutnomen/refseq.html#exinnr).
For separation of LM-derived LECs and fibroblasts we performed a ’classical’ mechanical
isolation procedure, the cell sweeping procedure, originally described by Dr. Judah Folkman
[28]. The reason for not performing immuno-isolation techniques with surface molecules such
as Podoplanin (PDPN) and LYVE-1 is an obvious one. LM are often derived from lymphatic
collectors. Importantly, collector LECs, but also numerous lymph node LECs [29] are negative
for the two markers [2, 23], which also applies to 1/3 of LM [6]. The most reliable marker for
LECs from all parts of the lymphovascular system, including the lymph nodes, is double-stain-
ing for CD31 and Prox1 [30, 29, 23]. This, together with Dapi, enables counting of positive vs.
negative cells, and exact quantification. Remaining cells are mostly fibroblasts, which escaped
the cell sweeping. Previous studies who have used CD31 plus PDPN sorting of LM-LECs
Fig 6. Proliferation studies with PIK3CA inhibitor Wortmannin on Ly-LEC (left side, A—C) and HD-LEC (right
side, D—F), after 0, 24, 48 and 72 hours (h). 0 h values were set to 100%. Concentrations are indicated. Shown are the
mean values of n = 3 independent experiments with each 5–8 replicates.
https://doi.org/10.1371/journal.pone.0200343.g006
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[9, 10] have obviously selected for lymphatic capillary-derived LECs and missed collector-
derived LECs.
We identified 1 new and 4 typical activating mutations in these exons, as well as a new in-
frame Glu109 deletion in Ly-LECs, but never in fibroblasts. This clearly shows that the muta-
tions are cell-type-specific. In two Ly-LEC lines we found new mutations. Thereby, the cell
line Ly-LEC2 showed a Glu109 deletion, which results in the loss of an amino acid in the
region linking PI3K-ABD and PI3K-RBD domains (https://ckb.jax.org/geneVariant/show?
geneVariantId=3785). Such deletion has been found, among other multiple mutations, in
several carcinomas [12, 13], but its effect on protein function has remained unknown. Here,
we have shown AKT-Ser473 hyperphosphorylation, but absence of ERK hyperphosphoryla-
tion, of Ly-LEC2, indicating that Glu109del serves as an activating mutation, which however
differs in its signaling cascade from the other activating mutations. In Ly-LEC-10 we found a
Fig 7. Proliferation studies with PIK3CA inhibitor Ly294002 on Ly-LEC (left side, A—C) and HD-LEC (right side,
D—F), after 0, 24, 48 and 72 hours (h). 0 h values were set to 100%. Concentrations are indicated. Shown are the
mean values of n = 3 independent experiments with each 5–8 replicates.
https://doi.org/10.1371/journal.pone.0200343.g007
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mutation in exon 10 (c.1636C>A; p.Gln546Lys = p.Q546K), which has also not been detected
in Ly-LECs before. Again, this mutation has previously been found in tumors such as ovarian
tumors, glioblastoma, uterine carcinosarcoma, and squamous cell carcinoma [14, 15]; also see:
https://www.ncbi.nlm.nih.gov/pubmed/26619011). Both AKT-Ser473 and ERK hyperpho-
sphorylation in Ly-LEC10 shows that this mutation represents an activating mutation as well.
Previously, the p.H1047L mutation in the PIK3CA gene, in addition to a premature stop
codon in the PI3K regulatory subunit-3 (PIK3R3), has been found in a LM-derived LEC line
isolated at the Boston Children’s Hospital [9]. The authors also observed high angiogenic
potential of this cell line in vitro, as well as hyperphosphorylation of AKT-Thr308. Corre-
spondingly, in another four LM-derived LEC lines isolated at the Cincinnati Children’s Hospi-
tal, p.E542K and p.E545A mutations, lymphangiogenic phenotype and AKT activation were
identified [10]. We found hyperphosphorylation of AKT-Ser473 in LM-derived LECs, which
Fig 8. Proliferation studies with PIK3CD inhibitor CAL-101 (Idealisib) on Ly-LEC (left side, A—C) and HD-LEC
(right side, D—F), after 0, 24, 48 and 72 hours (h). 0 h values were set to 100%. Concentrations are indicated. Shown
are the mean values of n = 3 independent experiments with each 5–8 replicates.
https://doi.org/10.1371/journal.pone.0200343.g008
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supports the well-known observation of the activation of angiogenesis via the PI3K—AKT—
mTOR pathway [16]. Activating mutations in the PIK3CA gene have very recently also been
found in patients with venous malformations [31, 32], underlining the need for a causal ther-
apy of vascular malformations, e.g. with kinase inhibitors.
We have therefore tested a panel of 7 kinase inhibitors on LM-derived Ly-LEC in compari-
son to normal HD-LECs. We studied BKM-120, Wortmannin, Ly294002, which are inhibitors
of PIK3CA, CAL-101 (Idelalisib), an inhibitor of PIK3CD, MK-2206, an AKT inhibitor, Sora-
fenib, a multi-kinase inhibitor, and rapamycin, which inhibits mTOR. We observed significant
dose-dependent growth inhibition with all inhibitors used, however, normal LECs responded
similarly. Of note, the PIK3CD inhibitor CAL-101 [33] showed no effects, or effects only at
Fig 9. Proliferation studies with AKT inhibitor MK2206 on Ly-LEC (left side, A—C) and HD-LEC (right side, D—
F), after 0, 24, 48 and 72 hours (h). 0 h values were set to 100%. Concentrations are indicated. Shown are the mean
values of n = 3 independent experiments with each 5–8 replicates.
https://doi.org/10.1371/journal.pone.0200343.g009
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very high dosage, which underlines the fact that PIC3CA, but not PIC3CD, is involved in the
disease.
In contrast to a previous study, which reported on specific rapamycin effects on LM-
derived LECs (a single cell line was used), but not healthy LECs [9], we did not detect an
immediately obvious therapeutic window in vitro, neither for rapamycin, nor for the other
kinase inhibitors tested, with the exception that, however, MK-2206 might be worth to be fur-
ther tested with ’typical’ lymphatic malformations. After 48h, we observed reduction of cell
numbers below the initial value in 2 out of 3 LM-derived Ly-LEC lines with 25μM MK-2206,
but not in healthy HD-LECs. Thereby, the LM-derived LEC line that did not respond so well
was Ly-LEC-2, which possesses the Glu109 deletion and no ERK hyperphosphorylation. Tests
with other Ly-LEC lines will have to determine if MK-2206 might be the inhibitor of choice
Fig 10. Proliferation studies with multi-kinase inhibitor Sorafenib on Ly-LEC (left side, A—C) and HD-LEC
(right side, D—F), after 0, 24, 48 and 72 hours (h). 0 h values were set to 100%. Concentrations are indicated. Shown
are the mean values of n = 3 independent experiments with each 5–8 replicates.
https://doi.org/10.1371/journal.pone.0200343.g010
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for patients with PIK3CA mutations accounting for the majority of cases. Thereby, the possi-
bility that a second mutation may accompany the PIK3CA mutation has to be taken into
account [34].
Can the in vitro data be directly transferred to the situation in patients, to infants or adults?
It is known that blood vascular endothelial cells in adults hardly proliferate [35]. To the best of
our knowledge, proliferation of blood vascular and lymphatic endothelial cells has never been
studied in children, but there seems to be no doubt that the values are significantly higher.
With immunofluorescence we have previously observed expression of VEGFR-2 and -3 in
blood vessels and lymphatics of infants [2], which underlines the immaturity of vessels in early
years after birth. Nevertheless, the turnover of endothelial cells in infants is likely to be signifi-
cantly lower than the proliferation of the cells in vitro. Therefore, our in vitro data may not be
Fig 11. Proliferation studies with mTOR inhibitor rapamycin on Ly-LEC (left side, A—C) and HD-LEC (right
side, D—F), after 0, 24, 48 and 72 hours (h). 0 h values were set to 100%. Concentrations are indicated. Shown are the
mean values of n = 3 independent experiments with each 5–8 replicates.
https://doi.org/10.1371/journal.pone.0200343.g011
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directly transferrable to the in vivo situation, and a therapeutic window for kinase inhibitors
may well be present. It goes without saying that children must be closely monitored under
treatment. Even more likely, a therapeutic window may be present for the treatment of adult
LM-patients.
In summary, our studies show that activating PIK3CA mutations in LM are specifically
localized in LECs. We identified a new mutation in exon 10 and a Glu109 deletion of the gene
and show that several kinase inhibitors have the potential to block LEC proliferation. However,
since these effects are not restricted to mutated cells, caution is advisable when treating young
patients.
Materials and methods
Isolation and culture of cells
The Ethics Committee of the University Medical Hospital Go¨ttingen approved this study
(application no.: 18/1/18). Studies were performed with the informed and written consent of
the patients or their legal representatives. Lymphangioma/LM-derived LECs (Ly-LECs) and
LM-derived fibroblasts (Ly-F) were isolated as described [11]. Briefly, we used the cell sweep-
ing procedure, a purely mechanical method which was originally introduced by Judah Folk-
man [28]. LM tissue was cut into small pieces and cultured in endothelial growth medium
(MV2), including supplements, fetal bovine serum (PromoCell, Heidelberg, Germany), and
1% penicillin/streptomycin (Thermo-Fisher, Darmstadt, Germany). Ly-LECs and fibroblasts
(Ly-F) that migrated out were separated mechanically, and cells were further cultured at 37˚C
and 5% CO2. The lymphendothelial identity was regularly controlled by immunocytology with
antibodies against CD31/PECAM-1 (BD, Heidelberg, Germany) and PROX1 (ReliaTech, Wol-
fenbu¨ttel, Germany). Purity of the cells was at least 80–90%. Pure LM-derived fibroblasts (Ly-
F) were cultured in RPMI 1640 (Lonza, Basel, Switzerland), and characterized by their mor-
phology, growth behavior and antibodies against vimentin and α smooth muscle actin
(αSMA). Normal foreskin-derived LECs (HD-LEC) were bought from PromoCell (Heidel-
berg, Germany) and controlled by their CD31/PROX1 expression. Cells were cultured as
described above.
Mutation analysis of Ly-LEC and Ly-F
Genomic DNA of LM-derived cell lines (Ly-LEC, Ly-F) and normal lymphatic endothelial
cells (HD-LEC) was extracted using DNeasy blood & tissue kit (Qiagen) according to the
manufacturer’s protocol. For sequence analysis, exons 8, 10 and 21 (≙ coding exons 7, 9 and
20) of PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha;
NM_006218.2) were amplified from the genomic DNA using the primer sets depicted in
Table 2. For exon 10, it was verified not to amplify parts of the pseudogene. PCR products
were purified and used in the sequencing reaction, which included BigDye and sequencing
primers, and was performed on ABI 3500 (Applied Biosystems, Thermo-Fisher, Foster City,
CA). Data were analyzed using the software SeqPilot (JSI medical systems GmbH, Ettenheim,
Germany).
Immunocytology
Cells were seeded on chamber slides (BD). After 24 hours, immunostaining was performed as
follows: after short (1 min) 4% paraformaldehyde (PFA) fixation, cells were washed with PBS
and incubated in bovine serum albumin (BSA). Then 0.1% Tween/PBS (for better PROX1
staining results—30 seconds) was applied, followed by immunostaining. Anti-human PROX1
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(1:200, ReliaTech, Wolfenbu¨ttel, Germany), anti-human CD31 (1:50; BD, NJ, USA), mouse-
anti-human vimentin (1:1, DAKO; clone V9), and mouse-anti-human smooth muscle α-actin
(αSMA) (1:500, Sigma, clone 1A4) antibodies were incubated for one hour, rinsed with PBS,
and then secondary antibody staining with Alexa594-conjugated goat-anti-rabbit and Alex-
a488-conjugated goat-anti-mouse (1:200; ThermoFisher Scientific, MA, USA) was performed.
Cells were counter-stained with Dapi and analyzed with AxioImager Z.1 (Zeiss, Go¨ttingen,
Germany).
Western blot
Cells were washed twice with 5 ml DPBS (Pan Biotech; Aidenbach, Germany) and 1 mM
sodium orthovanadate (Sigma-Aldrich; Steinheim, Germany) and subsequently lysed with
RIPA buffer for 10 minutes on crushed ice. Samples were transferred to micro tubes (Sarstedt;
Nu¨rnberg, Germany) and centrifuged by 20,800x g for 15 minutes. Protein lysates were col-
lected and used for SDS-PAGE according to standard procedures (Bio-Rad Laboratories;
Mu¨nchen, Germany). Proteins were transferred to PVDF membranes (Roth; Karlsruhe, Ger-
many), which were then washed with TBST (0.1% Tween 20) for 10 minutes and blocked for
one hour in blocking buffer (5% BSA in TBST 0.1%). Primary antibodies were: pAKT-Ser473,
1:500 in 5% BSA (rabbit mAb: Cell Signaling Technology, #4060); total AKT (rabbit pAb: Cell
Signaling, #9272, 1:1000); phospho-p44/42MAPK (pERK1/2), Thr202/Tyr204, (rabbit mAb:
Cell Signaling, #4370); p44/42MAPK (ERK1/2) (rabbit mAb: Cell Signaling, #4695); and per-
oxidase-conjugated α-tubulin, 1:10000 (Abcam, ab40742). Incubation was at 4 ˚C overnight.
After washing with TBST (0.1% Tween 20) for 10 min., the peroxidase-conjugated secondary
anti-rabbit IgG, 1:2000 (Santa Cruz; USA) were incubated for one hours. After washing, anti-
gen-antibody complexes were visualized with ECL and Chemidoc Touch Imaging System
(Bio-Rad).
Proliferation assays
Proliferation assays were performed as described [36]. Briefly, 5000 cells were seeded into
96-well cell culture plates (Sarsted, Nu¨mbrecht, Germany), and allowed to adhere overnight.
Inhibitors or solvent controls were added at indicated concentrations. Cells were fixed with
4% glutaraldehyde after 24, 48 and 72 hours, stained with crystal violet (0.01% in deionized
water), and absorption was measured at 570 nm with a microplate reader. Data are presented
as the mean values of n = 3 independent experiments with each 5–8 replicates.
Table 2. Primers used for mutation analyses of PIK3CA.
Primer Fw (5’– 3’) Rev (5’– 3’)
Exon 8 GGTCAGCTCTCCCAGCGATGGAAAGAATG
GGCTTAAACCTTG
CAGCTCTCCCACAGGCGAATAAGAGAG
AAGGTTTGACTGCC
GGTCAGCTCTCCCAGCGATAGGAAAGAAT
GGGCTTAAACCT
CAGCTCTCCCACAGGCGAAAAGAGAG
AAGGTTTGACTGCCA
Exon 10 GGTCAGCTCTCCCAGCGATAGATTGGTTC
TTTCCTGTCTCTGA
CAGCTCTCCCACAGGCGAATGAGATCA
GCCAAATTCAGTTATTT
CAGCTCTCCCACAGGCGAACATTTAAT
GTGCCAACTACCAATGT
Exon 21 GGTCAGCTCTCCCAGCGATCCTGAAGGTA
TTAACATCATTTGCTCC
CAGCTCTCCCACAGGCGAAGCCTGCTG
AGAGTTATTAACAGTGC
Seq_R CAGCTCTCCCACAGGCGAA
Seq_F GGTCAGCTCTCCCAGCGAT
https://doi.org/10.1371/journal.pone.0200343.t002
PIK3CA mutations in lymphatic malformations
PLOS ONE | https://doi.org/10.1371/journal.pone.0200343 July 9, 2018 15 / 18
Kinase inhibitors
All kinase inhibitors were bought from Seleckchem (Absource Diagnostics, Munich, Ger-
many). We used Buparlisib/BKM120, Wortmannin, and Ly294002 (to inhibit PIK3CA), CAL-
101/Idelalisib (to inhibit PIK3CD), MK2206 (AKT inhibitor), Sorafenib (multi-kinase inhibi-
tor), and rapamycin (mTOR inhibitor). Inhibitors were diluted in DMSO (Sigma-Aldrich,
Taufkirchen, Germany). Controls were performed with DMSO, corresponding to the highest
concentration used in experimental groups.
Statistical methods
Statistical analyzes were conducted by two-way-ANOVA with STATISTICA software (Statsoft,
Tulsa, Oklahoma). Normal distribution was verified before testing. The standard error of the
mean (SEM) was calculated and is shown in the graphs. Significant differences were consid-
ered as p-value 0.05 [], p 0.01 [] and p 0.001 [].
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